CERo Therapeutics enters into $2.085M convertible promissory note with SRX Global

CERO THERAPEUTICS HOLDINGS, INC.

Maximum loan amount $2,085,200; $750,000 funded May 23, $663,600 June 23, $671,600 July 14, 2026.
Note bears 10% interest per annum, matures May 28, 2027.
Convertible at lesser of $0.05 or 80% of avg of 5 lowest intraday prices in prior 20 days; 4.99% ownership cap.
Company must file registration statement for resale of shares issuable upon conversion.
Issuance exempt under Section 4(a)(2) and Rule 506(b); Lender is accredited investor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.